HomeComparePNT vs QSR

PNT vs QSR: Dividend Comparison 2026

PNT yields 16.00% · QSR yields 3.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PNT wins by $32.3K in total portfolio value
10 years
PNT
PNT
● Live price
16.00%
Share price
$12.50
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.0K
Annual income
$4,284.03
Full PNT calculator →
QSR
QSR
● Live price
3.40%
Share price
$73.76
Annual div
$2.51
5Y div CAGR
-0.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.7K
Annual income
$387.88
Full QSR calculator →

Portfolio growth — PNT vs QSR

📍 PNT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPNTQSR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PNT + QSR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PNT pays
QSR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PNT
Annual income on $10K today (after 15% tax)
$1,360.00/yr
After 10yr DRIP, annual income (after tax)
$3,641.43/yr
QSR
Annual income on $10K today (after 15% tax)
$289.25/yr
After 10yr DRIP, annual income (after tax)
$329.70/yr
At 15% tax rate, PNT beats the other by $3,311.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PNT + QSR for your $10,000?

PNT: 50%QSR: 50%
100% QSR50/50100% PNT
Portfolio after 10yr
$40.8K
Annual income
$2,335.95/yr
Blended yield
5.72%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PNT right now

PNT
Analyst Ratings
7
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$13.75
+10.0% upside vs current
Range: $10.00 — $17.00
Altman Z
16.8
Piotroski
6/9
QSR
No analyst data
Altman Z
1.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PNT buys
0
QSR buys
0
No recent congressional trades found for PNT or QSR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPNTQSR
Forward yield16.00%3.40%
Annual dividend / share$2.00$2.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-0.8%
Portfolio after 10y$57.0K$24.7K
Annual income after 10y$4,284.03$387.88
Total dividends collected$28.6K$3.7K
Payment frequencyquarterlyquarterly
SectorStockStock

Year-by-year: PNT vs QSR ($10,000, DRIP)

YearPNT PortfolioPNT Income/yrQSR PortfolioQSR Income/yrGap
1← crossover$12,300$1,600.00$11,038$337.57+$1.3KPNT
2$15,000$1,839.25$12,156$345.43+$2.8KPNT
3$18,147$2,096.29$13,359$352.69+$4.8KPNT
4$21,787$2,370.08$14,654$359.36+$7.1KPNT
5$25,971$2,659.38$16,045$365.45+$9.9KPNT
6$30,752$2,962.76$17,539$370.97+$13.2KPNT
7$36,183$3,278.63$19,143$375.96+$17.0KPNT
8$42,322$3,605.31$20,863$380.42+$21.5KPNT
9$49,225$3,941.04$22,708$384.39+$26.5KPNT
10$56,955$4,284.03$24,685$387.88+$32.3KPNT

PNT vs QSR: Complete Analysis 2026

PNTStock

POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.

Full PNT Calculator →

QSRStock

Restaurant Brands International Inc. operates as quick service restaurant company in Canada and internationally. It operates through four segments: Tim Hortons (TH), Burger King (BK), Popeyes Louisiana Kitchen (PLK), and Firehouse Subs (FHS). The company owns and franchises TH chain of donut/coffee/tea restaurants that offer blend coffee, tea, and espresso-based hot and cold specialty drinks; and fresh baked goods, including donuts, Timbits, bagels, muffins, cookies and pastries, grilled paninis, classic sandwiches, wraps, soups, and others. It is also involved in owning and franchising BK, a fast food hamburger restaurant chain, which offers flame-grilled hamburgers, chicken and other specialty sandwiches, french fries, soft drinks, and other food items; and PLK quick service restaurants that provide Louisiana style fried chicken, chicken tenders, fried shrimp and other seafood, red beans and rice, and other regional items. In addition, the company owns and franchises FHS restaurants quick service restaurants that offer subs, soft drinks, and local specialties. As of February 15, 2022, the company had approximately 29,000 restaurants in 100 countries under the Tim Hortons, Burger King, Popeyes, And Firehouse Subs brands. Restaurant Brands International Inc. was founded in 1954 and is headquartered in Toronto, Canada.

Full QSR Calculator →
📬

Get this PNT vs QSR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PNT vs SCHDPNT vs JEPIPNT vs OPNT vs KOPNT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.